The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
Antivir Ther
; 9(5): 811-7, 2004 Oct.
Article
em En
| MEDLINE
| ID: mdl-15535419
ABSTRACT
We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI) -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Lamivudina
/
Terapia Antirretroviral de Alta Atividade
/
Hepatite B
Tipo de estudo:
Clinical_trials
/
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Antivir Ther
Assunto da revista:
TERAPIA POR MEDICAMENTOS
/
VIROLOGIA
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Itália